Marina Bio Lab

Medical Professionals

Medical Professionals

Home > Medical Professionals

ColoScape™ Test

Colorectal cancer is the second leading cause of cancer death in the US when women and men are combined. It is estimated that 50,630 deaths (27,390 men and 23,240 women will be attributed to Colorectal cancer this year. According to the American Cancer Society, the guideline for colorectal screening is to start the colorectal cancer screening at age 45. However, among the 98 million Americans aged 50 to 84, one-third of them are not screened for colorectal cancer for different reasons.

ColoScape™ Test is a novel highly sensitive diagnostic test that uses qPCR-based multigene panel for the qualitative detection of colorectal cancer-associated gene mutations and methylation markers in liquid biopsy samples. The test panel targets 61 mutations in 8 genes and 7 methylation markers mostly associated with colorectal cancer. The test utilizes DiaCarta’s proprietary XNA technology which leverages a sequence-specific clamp made by xeno-nucleic acid (XNA) to clamp the wild type sequences.ColoScape™ Test is a novel highly sensitive diagnostic test that uses qPCR-based multigene panel for the qualitative detection of colorectal cancer-associated gene mutations and methylation markers in liquid biopsy samples. The test panel targets 61 mutations in 8 genes and 7 methylation markers mostly associated with colorectal cancer. The test utilizes DiaCarta’s proprietary XNA technology which leverages a sequence-specific clamp made by xeno-nucleic acid (XNA) to clamp the wild type sequences.

Test configuration of ColoScape™

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare